Nine Ten Capital reports 3.4% iRadimed (IRMD) ownership stake

Rhea-AI Filing Summary

Nine Ten Capital Management LLC and related reporting persons report beneficial ownership of iRadimed Corp common stock on a Schedule 13G/A Amendment No. 6. They disclose holding 428,477 shares, representing 3.4% of the common stock, as of December 31, 2025.

The filers report sole voting and sole dispositive power over these 428,477 shares. They certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iRadimed Corp.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

iRadimed Corp

(Name of Issuer)

Common

(Title of Class of Securities)

46266A109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 46266A109

1

Names of Reporting Persons

Nine Ten Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ILLINOIS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 428,477.00
6	Shared Voting Power
7	Sole Dispositive Power 428,477.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

428,477.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 46266A109

1

Names of Reporting Persons

Nine Ten Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ILLINOIS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 428,477.00
6	Shared Voting Power
7	Sole Dispositive Power 428,477.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

428,477.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 46266A109

1

Names of Reporting Persons

Russell Mollen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ILLINOIS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 428,477.00
6	Shared Voting Power
7	Sole Dispositive Power 428,477.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

428,477.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: iRadimed Corp
(b)	Address of issuer's principal executive offices: 1025 WILLA SPRINGS DR., WINTER SPRINGS, FL 32708
Item 2.
(a)	Name of person filing: Nine Ten Capital Management LLC
(b)	Address or principal business office or, if none, residence: 20 N Wacker Dr., Ste 2825, Chicago, IL 60606
(c)	Citizenship: United States
(d)	Title of class of securities: Common
(e)	CUSIP No.: 46266A109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 428,477
(b)	Percent of class: 3.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 428,477
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of: 428,477
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nine Ten Capital Management

Signature:	Michelle Katauskas
Name/Title:	CCO
Date:	2/10/2026

Nine Ten Partners LP

Signature:	Michelle Katauskas
Name/Title:	CCO
Date:	2/10/2026

Russell Mollen

Signature:	Russell Mollen
Name/Title:	President
Date:	2/10/2026

FAQ

What ownership stake in iRadimed Corp (IRMD) does Nine Ten Capital report?

Nine Ten Capital Management LLC and related reporting persons report beneficial ownership of 428,477 iRadimed Corp common shares, representing 3.4% of the class. This stake is reported as of December 31, 2025 under a Schedule 13G/A Amendment No. 6 filing.

What type of security in iRadimed Corp (IRMD) is covered by this Schedule 13G/A?

The filing covers common stock of iRadimed Corp, identified by CUSIP 46266A109. All reported ownership figures, including the 428,477 shares and 3.4% beneficial ownership, relate specifically to this class of common equity securities.

How much voting and dispositive power does Nine Ten Capital have over IRMD shares?

The reporting persons disclose sole voting power and sole dispositive power over 428,477 iRadimed Corp common shares. They report no shared voting or shared dispositive power over these securities in the ownership breakdown provided with the Schedule 13G/A.

Is Nine Ten Capital filing as a passive investor in iRadimed Corp (IRMD)?

Yes. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of iRadimed Corp, consistent with a passive investment reporting position under Schedule 13G.

Why does the Schedule 13G/A note ownership of 5 percent or less of IRMD?

Item 5 states ownership of 5 percent or less of the class, confirming the reported 3.4% stake. This indicates the filers’ beneficial ownership is below the 5% threshold while still requiring disclosure under the applicable Schedule 13G rules and amendment framework.

Who are the reporting persons named in the iRadimed Corp (IRMD) Schedule 13G/A?

The filing identifies Nine Ten Capital Management LLC, Nine Ten Partners, and Russell Mollen as reporting persons. Each reports beneficial ownership of 428,477 iRadimed Corp common shares, equal to 3.4% of the outstanding class as of December 31, 2025.